X.T.L. Biopharmaceuticals Ltd

Research X.T.L. Biopharmaceuticals Ltd (XTLB) on Bullrun: market cap USD 5.58M. Explore financials, valuation history, model signals, and stock context.

Key Metrics

• TickerXTLB
• ExchangeNASDAQ
• CountryIsrael
• SectorHealthcare
• IndustryBiotechnology
• CurrencyUSD
• Market capUSD 5.58M
• Financial periodQ4 2024
• RevenueUSD 289.00K
• Net income-USD 255.00K
• Free cash flow-USD 1.67M
• Gross margin-14.9%

Valuation Snapshot

latest market cap is USD 5.58M.

About X.T.L. Biopharmaceuticals Ltd

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel. Its lead drug candidate is hCDR1, which is a Phase II-ready asset for the treatment of systemic lupus erythematosus and Sjogren's syndrome. The company has a licensing agreement with Yeda Research and Development Company Limited for the research, development, and commercialization of hCDR1 for various indications.

Frequently asked questions

What is X.T.L. Biopharmaceuticals Ltd's market cap?

X.T.L. Biopharmaceuticals Ltd's market capitalization is USD 5.58M.

What does X.T.L. Biopharmaceuticals Ltd do?

XTL Biopharmaceuticals Ltd., a biopharmaceutical company, engages in the acquisition and development of pharmaceutical drugs for the treatment of autoimmune diseases in Israel.